Korea Investment CORP Raises Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Korea Investment CORP increased its stake in Thermo Fisher Scientific by 8.2%, acquiring an additional 26,965 shares, bringing its total holdings to 355,698 shares worth approximately $176.99 million.
• The company reported $5.36 earnings per share (EPS) for its most recent quarter, exceeding analyst expectations of $5.22, with revenue also surpassing estimates at $10.86 billion.
• Thermo Fisher Scientific announced a quarterly dividend of $0.43 per share, with a scheduled payment date of October 15th, contributing to an annualized dividend yield of 0.4%.

Korea Investment CORP grew its stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 8.2% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 355,698 shares of the medical research company's stock after buying an additional 26,965 shares during the quarter. Korea Investment CORP owned 0.09% of Thermo Fisher Scientific worth $176,995,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Cypress Advisory Group LLC bought a new position in shares of Thermo Fisher Scientific during the 4th quarter valued at $253,000. Mondrian Investment Partners LTD grew its holdings in shares of Thermo Fisher Scientific by 146.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock valued at $106,738,000 after purchasing an additional 127,357 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Thermo Fisher Scientific by 22.0% during the 1st quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after purchasing an additional 877 shares during the last quarter. Deutsche Bank AG grew its holdings in shares of Thermo Fisher Scientific by 9.5% during the 4th quarter. Deutsche Bank AG now owns 1,321,633 shares of the medical research company's stock valued at $687,553,000 after purchasing an additional 114,277 shares during the last quarter. Finally, Hancock Whitney Corp grew its holdings in shares of Thermo Fisher Scientific by 0.6% during the 4th quarter. Hancock Whitney Corp now owns 5,386 shares of the medical research company's stock valued at $2,802,000 after purchasing an additional 30 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Trading Up 3.4%

Shares of TMO traded up $16.4780 during trading hours on Friday, reaching $500.2380. 1,778,365 shares of the company traded hands, compared to its average volume of 2,406,376. The company's fifty day moving average price is $443.02 and its two-hundred day moving average price is $457.46. The company has a market capitalization of $188.89 billion, a price-to-earnings ratio of 28.93, a price-to-earnings-growth ratio of 2.58 and a beta of 0.74. The company has a quick ratio of 1.50, a current ratio of 1.93 and a debt-to-equity ratio of 0.65. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $627.88.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 earnings per share for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The firm had revenue of $10.86 billion for the quarter, compared to analyst estimates of $10.68 billion. During the same quarter in the previous year, the firm posted $5.37 EPS. The company's revenue for the quarter was up 2.9% compared to the same quarter last year. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Investors of record on Monday, September 15th will be given a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Analysts Set New Price Targets

Several equities analysts recently commented on TMO shares. Robert W. Baird increased their target price on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Evercore ISI cut their price target on shares of Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating on the stock in a report on Tuesday, July 8th. Hsbc Global Res cut shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. HSBC restated a "hold" rating and issued a $510.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday, July 24th. Finally, Argus decreased their price objective on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a research report on Tuesday, April 29th. Sixteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $593.00.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction dated Friday, July 25th. The shares were sold at an average price of $479.98, for a total transaction of $191,992.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares of the company's stock, valued at $10,735,712.66. This trade represents a 1.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Wednesday, August 6th. The shares were sold at an average price of $451.82, for a total transaction of $4,518,200.00. Following the transaction, the chief executive officer directly owned 115,174 shares of the company's stock, valued at approximately $52,037,916.68. This trade represents a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 18,896 shares of company stock valued at $8,593,838. 0.33% of the stock is currently owned by corporate insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.